Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi Aventis and Exelixis, a biotechnology company, have signed a global licencing agreement for XL147 and XL765, and formed an exclusive collaboration for the discovery of inhibitors of phosphoinositide-3 kinase (PI3K) for the management of solid malignancies.
Subscribe to our email newsletter
Under the agreement, Sanofi Aventis will have a worldwide licence to XL147, an oral PI3K inhibitor, and XL765, an oral dual inhibitor of PI3K and mTOR. Both the compounds are in phase I clinical trial. Sanofi Aventis will have sole responsibility for all subsequent clinical, regulatory, manufacturing and commercial activities. Exelixis will participate in ongoing and potential future clinical trials.
Moreover, the two companies will join research efforts to establish several preclinical programs related to isoform selective inhibitors of PI3K.
Sanofi-aventis will pay Exelixis cash payment as well as development and milestone payments that could reach over $1 billion for existing and future programs.
Marc Cluzel, Senior Vice President of Research and Development at Sanofi Aventis, said: “we are very excited about integrating such novel targeted therapies with high therapeutic potential in our portfolio.”
“We look forward to combining our efforts with Exelixis to develop innovative drugs in the best interest of patients suffering from cancers. This alliance is aligned with our strategy to create value through strategic partnerships that deliver new therapeutic options”, he added.